The goal of the study is to develop an algorithm that associates between biomarkers detected in biospecimen of NSCLC patients, and their:
- Response to treatment
- Clinical benefit parameters such as PFS and OS.
- Adverse events to immune check inhibitor therapy
- Biological mechanisms involved in response or resistance to immune check inhibitor therapy.
Patients will provide plasma, PBMCs, stool and tissue samples (where applicable) before and during treatment.
Clinical data, including disease history, given treatment, response evaluation and adverse events to the treatment will be recorded.
Samples will be analysed as follows –
- Proteomic features (Plasma proteomics)
- Epigenetic patterns (cell free DNA)
- ctDNA mutation analysis
- PBMC subpopulations
- Microbiome profiling (Stool)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.